Is D’OXYVA® safe for my patients (humans and pets)?
Circularity Healthcare operates a state-of-the-art supply chain and quality management system (QMS) for manufacturing. Circularity has certificates of registration for IS EN ISO13485:2012 (European Union) and ISO13485:2003 under CMDCAS (Canada), which it has been implementing since 2013.
D’OXYVA is a CE-marked medical device (Class I, low risk) for delivery of medications via the skin. Circularity is seeking approval from the U.S. FDA and other countries for delivery of medical gases such as medical carbon dioxide (USP UN1013) via a novel, patented, non-invasive transdermal route with D’OXYVA to treat various widespread conditions.
Medical carbon dioxide is manufactured and delivered under applicable standards per each country’s regulatory requirements. In the United States, the Food and Drug Administration has cleared the use of medical carbon dioxide through inhalation for humans but not yet through transdermal delivery with D’OXYVA. Transportation of medical carbon dioxide via any postal or courier service requires a certification for handling dangerous goods (HAZMAT) by the U.S. Department of Transportation (DOT).
Possible risks of and adverse reactions to the D’OXYVA® device and water vapor with high CO2 concentration (not yet recorded):
- Transient hypotension FZ©
- Orthostatic intolerance
- Facial flushing
- Severe hypertension
- New cardiac infarctions
- Aortic and mitral valve stenosis
- Severe congenital heart failure
- Cor pulmonale
- Bronchopulmonary diseases accompanied by hypercapnia
- Acute inflammatory vascular diseases
Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D’OXYVA® for Rapid, Economical and Noninvasive Home Treatment of Diabetic Foot Ulcers (DFU)
PASADENA, Calif., Feb. 1, 2021 5:31 AM PST (MORNINGSTAR) Addressing urgent and increased DFU problem related to pandemic lockdowns. Circularity Healthcare announced it had successfully executed a contract with the
LOS ANGELES (PRWEB) DECEMBER 11, 2019 Circularity is partnering with Telly Award-Winning “Behind the Scenes” to provide regular, ongoing, high-quality content from leading experts in a variety of fields with an
Switch To D'OXYVA®.
The only gentle, rapid, and painless transdermal solution without breaking the layers of the skin.
D’OXYVA® (deoxyhemoglobin vasodilator) biotechnology provides an inexpensive, simple and effective method of mild to severe chronic wound care. Its fully noninvasive transdermal approach delivers a host of benefits including but not limited to significant blood flow in the microcirculation (perfusion index), oxygen saturation (SpO2), nutrients, nerve stimulation (parasympathetic), which together are crucial for the complete and painless wound healing process.
Get in touch to avail D’OXYVA® for rapid chronic wound treatment.